AbbVie [ABBV] vs Amgen [AMGN] Detailed Stock Comparison

AbbVie Inc.

NYSE
Loading...

Amgen Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: AbbVie Inc. wins in 9 metrics, Amgen Inc. wins in 12 metrics, with 0 ties. Amgen Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric AbbVie Inc. Amgen Inc. Better
P/E Ratio (TTM) 83.46 24.22 Amgen Inc.
Price-to-Book Ratio -108.79 21.46 Amgen Inc.
Debt-to-Equity Ratio -21.19 640.28 Amgen Inc.
PEG Ratio -0.01 0.22 Amgen Inc.
EV/EBITDA 14.31 13.97 Amgen Inc.
Profit Margin (TTM) 6.91% 20.98% Amgen Inc.
Operating Margin (TTM) 34.11% 30.55% AbbVie Inc.
EBITDA Margin (TTM) 34.11% 30.55% AbbVie Inc.
Return on Equity 6,225.00% 106.10% AbbVie Inc.
Return on Assets (TTM) 9.81% 7.93% AbbVie Inc.
Free Cash Flow (TTM) $17.82B $8.10B AbbVie Inc.
Dividend Yield 3.10% 3.30% Amgen Inc.
1-Year Return 19.18% 20.32% Amgen Inc.
Price-to-Sales Ratio (TTM) 5.72 5.06 Amgen Inc.
Enterprise Value $418.50B $232.21B AbbVie Inc.
EV/Revenue Ratio 6.84 6.32 Amgen Inc.
Gross Profit Margin (TTM) 72.61% 69.84% AbbVie Inc.
Revenue per Share (TTM) $35 $68 Amgen Inc.
Earnings per Share (Diluted) $2.37 $14.24 Amgen Inc.
Beta (Stock Volatility) 0.36 0.47 AbbVie Inc.
Short % of Float 1.27% 2.60% AbbVie Inc.

AbbVie Inc. vs Amgen Inc. Stock Performance Analysis

Loading Price Chart...

ABBV
AMGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
AbbVie Inc.0.04%2.58%8.40%22.13%18.90%10.98%
Amgen Inc.-1.31%1.39%7.42%-4.29%7.75%6.99%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
AbbVie Inc.19.18%64.26%101.32%279.49%590.09%590.09%
Amgen Inc.20.32%54.66%48.82%137.40%512.31%431.58%

Performance & Financial Health Analysis: AbbVie Inc. vs Amgen Inc.

MetricABBVAMGN
Market Information
Market Cap i$351.47B$187.93B
Market Cap CategoryMega capLarge cap
10 Day Avg. Volume i6,251,1012,431,753
90 Day Avg. Volume i6,859,5872,596,291
Last Close$254.49$350.53
52 Week Range$184.63 - $261.64$267.83 - $391.29
% from 52W High-2.73%-10.42%
All-Time High$261.64 (Jul 02, 2026)$391.29 (Mar 02, 2026)
% from All-Time High-2.73%-10.42%
Growth Metrics
Quarterly Revenue Growth0.10%0.09%
Quarterly Earnings Growth0.10%1.13%
Financial Health
Profit Margin (TTM) i0.07%0.21%
Operating Margin (TTM) i0.34%0.31%
Return on Equity (TTM) i62.25%1.06%
Debt to Equity (MRQ) i-21.19640.28
Cash & Liquidity
Book Value per Share (MRQ)$-1.85$16.07
Cash per Share (MRQ)$2.97$16.94
Operating Cash Flow (TTM) i$19.03B$9.96B
Levered Free Cash Flow (TTM) i$18.34B$7.50B
Dividends
Last 12-Month Dividend Yield i3.10%3.30%
Last 12-Month Dividend i$6.65$12.18

Valuation & Enterprise Metrics Analysis: AbbVie Inc. vs Amgen Inc.

MetricABBV (Apr 26, 2026)AMGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i83.4624.22
Forward P/E i12.3014.77
PEG Ratio i-0.010.22
Price to Sales (TTM) i5.725.06
Price to Book (MRQ) i-108.7921.46
Market Capitalization
Market Capitalization i$351.47B$187.93B
Enterprise Value i$418.50B$232.21B
Enterprise Value Metrics
Enterprise to Revenue i6.846.32
Enterprise to EBITDA i14.3113.97
Risk & Other Metrics
Beta i0.360.47
Book Value per Share (MRQ) i$-1.85$16.07

Financial Statements Comparison: AbbVie Inc. vs Amgen Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricABBV (2025)AMGN (2025)
Revenue/Sales i61.16B36.75B
Cost of Goods Sold i18.20B12.04B
COGS % of Revenue i29.8%32.8%
Gross Profit i42.96B24.71B
Gross Margin i70.2%67.2%
Research & Development i9.10B7.27B
Operating Income (EBIT) i20.09B9.08B
Operating Margin i32.8%24.7%
EBITDA i22.70B16.90B
EBITDA Margin i37.1%46.0%
Pre-Tax Income i6.60B8.98B
Pre-Tax Income % of Revenue i10.8%24.4%
Income Tax i2.36B1.27B
Income Tax % of Revenue i3.9%3.4%
Net Income (Profit) i4.23B7.71B
Profit Margin i6.9%21.0%

Balance Sheet & Liquidity Metrics

MetricABBV (2025)AMGN (2025)
Cash & Equivalents i5.23B9.13B
Total Current Assets i29.06B29.06B
Total Current Assets % of Revenue i47.5%79.1%
Total Current Liabilities i43.29B25.49B
Total Current Liabilities % of Revenue i70.8%69.4%
Long-Term Debt i58.94B50.01B
Long-Term Debt % of Revenue i96.4%136.1%
Total Shareholders Equity i-3.23B8.66B
Retained Earnings i-15.49B-25.11B
Retained Earnings % of Revenue i-25.3%-68.3%
Property, Plant & Equipment i8.79B5.22B

Cash Flow Statement Comparison

MetricABBV (2025)AMGN (2025)
Operating Cash Flow i19.94B10.51B
Operating Cash Flow % of Revenue i32.6%28.6%
Capital Expenditures i-1.21B-1.86B
Free Cash Flow i17.82B8.10B
FCF Margin i29.1%22.0%
Debt Repayment i-9.60B-5.00B
Common Stock Repurchase i-980.00M0

Short Interest & Institutional Ownership Analysis

MetricABBVAMGN
Shares Short i20.13M13.98M
Short Ratio i2.675.43
Short % of Float i1.27%2.60%
Shares Outstanding i1.77B538.80M
Float Shares i1.77B537.62M
% Held by Insiders i0.12%0.22%
% Held by Institutions i76.78%85.36%
% Held by Public i23.10%14.42%

Dividend Analysis & Yield Comparison: AbbVie Inc. vs Amgen Inc.

MetricABBVAMGN
Last 12-Month Dividend i$6.65$12.18
Last 12-Month Dividend Yield i3.10%3.30%
3-Year Avg Annual Dividend i$6.31$9.98
3-Year Avg Dividend Yield i0.91%0.77%
3-Year Total Dividends i$18.93$29.95
Ex-Dividend DateJan 16, 2026May 15, 2026